Skip to main content

Table 1 Therapy types included in the survey, each on a separate page. Therapies A–R were explicitly asked for, while S–U and V–X were included as complement

From: Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey

Annotation

Therapy type

A

131I-NaI for benign thyroid diseases

B

131I-NaI for thyroid remnant ablation of adults

C

131I-NaI for thyroid remnant ablation of children and young adults

D

131I-NaI for thyroid cancer therapy for adults

E

131I-NaI for thyroid cancer therapy for children and young adults

F

131I-mIBG for neuroblastoma

G

131I-mIBG for adult neuroendocrine tumors

H

177Lu-somatostatin analogues for neuroendocrine tumors

I

90Y-somatostatin analogues for neuroendocrine tumors

J

177Lu-PSMA therapy of castration resistant prostate cancer

K

90Y resin microspheres (SIR-Spheres®) for intra-arterial treatments in the liver

L

90Y glass microspheres (TheraSphere®) for intra-arterial treatments in the liver

M

Radiation synovectomy using 90Y-, 186Re-, or 169Er-colloids

N

153Sm-EDTMP (Quadramet®) for bone metastases

O

89SrCl2 (Metastron®) for bone metastases

P

223RaCl2 (Xofigo®) for bone metastases

Q

32P sodium-phosphate (Na3 32PO4) for myeloproliferative disease

R

90Y-ibritumomab-tiuxetan (Zevalin®) for B-cell lymphoma

S–U

Therapy using alpha emitting radionuclides other than 223Ra

V–X

Therapy using other radiopharmaceutical